Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas

Takao Ohtsuka, Takahiro Tomosugi, Ryuichiro Kimura, So Nakamura, Yoshihiro Miyasaka, Kohei Nakata, Yasuhisa Mori, Makiko Morita, Nobuhiro Torata, Koji Shindo, Kenoki Ohuchida, Masafumi Nakamura

研究成果: Contribution to journalReview article査読

5 被引用数 (Scopus)

抄録

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is characterized by cystic dilation of the pancreatic duct, caused by mucin hypersecretion, with slow progression via the adenoma–carcinoma sequence mechanism. Mutation of GNAS at codon 201 is found exclusively in IPMNs, occurring at a rate of 41–75%. Recent advances in molecular biological techniques have demonstrated that GNAS mutation might play a role in the transformation of IPMNs after the appearance of neoplastic cells, rather than in the tumorigenesis of IPMNs. GNAS mutation is observed frequently in the intestinal subtype of IPMNs with MUC2 expression, and less frequently in IPMNs with concomitant pancreatic ductal adenocarcinoma (PDAC). Research has focused on assessing GNAS mutation status in clinical practice using various samples. In this review, we discuss the clinical application of GNAS mutation assessment to differentiate invasive IPMNs from concomitant PDAC, examine the clonality of recurrent IPMNs in the remnant pancreas using resected specimens, and differentiate pancreatic cystic lesions using cystic fluid collected by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), duodenal fluid, and serum liquid biopsy samples.

本文言語英語
ページ(範囲)887-893
ページ数7
ジャーナルSurgery today
49
11
DOI
出版ステータス出版済み - 11 1 2019

All Science Journal Classification (ASJC) codes

  • 外科

フィンガープリント

「Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル